46,044 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Bought by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL bought a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 46,044 shares of the biotechnology company's stock, valued at approximately $495,000. Tudor Investment Corp ET AL owned 0.05% of Anavex Life Sciences at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC increased its position in Anavex Life Sciences by 70.4% during the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company's stock valued at $882,000 after buying an additional 64,101 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Anavex Life Sciences by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 42,565 shares of the biotechnology company's stock worth $242,000 after purchasing an additional 1,191 shares during the period. Watts Gwilliam & Co. LLC acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth about $279,000. Fiduciary Alliance LLC acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth about $119,000. Finally, SeaCrest Wealth Management LLC acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth about $164,000. Institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Stock Performance

AVXL stock traded down $0.01 during mid-day trading on Wednesday, reaching $8.11. The company had a trading volume of 455,487 shares, compared to its average volume of 1,219,808. The firm has a fifty day simple moving average of $8.92 and a 200 day simple moving average of $9.06. The company has a market capitalization of $692.37 million, a price-to-earnings ratio of -14.75 and a beta of 0.82. Anavex Life Sciences Corp. has a fifty-two week low of $3.51 and a fifty-two week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same period in the previous year, the company earned ($0.13) EPS. As a group, analysts predict that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AVXL. HC Wainwright restated a "buy" rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th. D. Boral Capital restated a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.